Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-99
SponsorUniversity of Aarhus
About this trial
The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients.
Eligibility criteria
Qualifiers
Pancreatic cancer patients considered to have a locally resectable or borderline resectable tumor by the local hepato-pancreato-biliary multidisciplinary team board
No liver metastases on CT
At least 18 years old and able to provide informed consent
Expected pancreatic ductal adenocarcinoma based on CT scan
Disqualifiers
Metastatic disease
Prior receipt of neoadjuvant chemotherapy or downstaging/-sizing treatment
Comorbidity rendering major surgery unfeasible (inoperable)
No informed consent
Trial design
Treatments tested in this trial
- Preoperative MRI
Treatment groups
200 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Aarhus
Lead sponsor
Rigshospitalet, Denmark
Collaborator
Aalborg University Hospital
Collaborator
Source ClinicalTrials.gov